4.5 Article

Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease

期刊

NEUROBIOLOGY OF AGING
卷 61, 期 -, 页码 75-81

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2017.09.011

关键词

Prognosis; Predementia Alzheimer's disease; Single subject; Gray matter networks; Clinical progression

资金

  1. Stichting Alzheimer Nederland
  2. Stichting VUmc fonds
  3. Boehringer Ingelheim Pharma GmbH Co KG, Germany
  4. Netherlands Organisation for Health Research and Development (ZonMW) [733050506]
  5. NIHR-UCLH Biomedical Research Centre

向作者/读者索取更多资源

We studied whether gray matter network parameters are associated with rate of clinical progression in nondemented subjects who have abnormal amyloid markers in the cerebrospinal fluid (CSF), that is, predementia Alzheimer's disease. Nondemented subjects (62 with subjective cognitive decline; 160 with mild cognitive impairment (MCI); age = 68 +/- 8 years; Mini-Mental State Examination (MMSE) = 28 +/- 2.4) were selected from the Amsterdam Dementia Cohort when they had abnormal amyloid in CSF (<640 pg/mL). Networks were extracted from gray matter structural magnetic resonance imaging (MRI), and 9 parameters were calculated. Cox proportional hazards models were used to test associations between each connectivity predictor and rate of progression to MCI or dementia. After a median time of 2.2 years, 122 (55%) subjects showed clinical progression. Lower network parameter values were associated with increased risk for progression, with the strongest hazard ratio of 0.29 for clustering (95% confidence interval = 0.12-0.70; p < 0.01). Results remained after correcting for tau, hippocampal volume, and MMSE scores. Our results suggest that at predementia stages, gray matter network parameters may have use to identify subjects who will show fast clinical progression. (C) 2017 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据